Daily Sepsis Research Analysis
Analyzed 23 papers and selected 3 impactful papers.
Summary
Analyzed 23 papers and selected 3 impactful articles.
Selected Articles
1. Mechanism of Gzma-mediated GEF-H1 activation in intestinal epithelial cells leading to intestinal barrier dysfunction in sepsis.
Using clinical samples, transcriptomics, in vitro co-culture, and CLP mice, the study shows that Gzma activates GEF-H1 via Ser886 dephosphorylation, triggering RhoA/ROCK signaling, cytoskeletal remodeling, and tight junction loss that impair the intestinal barrier. GEF-H1 knockout mitigated injury and improved survival, while Epothilone A suppressed GEF-H1 activity, restored barrier integrity, and enhanced survival in murine sepsis.
Impact: Identifies a mechanistic axis driving intestinal barrier failure in sepsis and demonstrates pharmacologic modulation with survival benefit, nominating GEF-H1 as a translational target.
Clinical Implications: Although preclinical, targeting GEF-H1 may protect the gut barrier and reduce multiple organ damage in sepsis. This supports biomarker-led selection of patients with barrier dysfunction and motivates early-phase trials of GEF-H1 modulators.
Key Findings
- Gzma levels were elevated in sepsis and correlated with disease severity in clinical samples and CLP mice.
- Gzma activated GEF-H1 by dephosphorylating Ser886, triggering RhoA/ROCK signaling, MLC2/LIMK/cofilin phosphorylation, and cytoskeletal remodeling.
- GEF-H1 knockout preserved tight junctions, reduced intestinal injury, and improved survival, while pharmacologic activation worsened damage.
- High-throughput screening identified Epothilone A as a GEF-H1 modulator that restored barrier integrity and improved survival in murine sepsis.
Methodological Strengths
- Multimodal validation across clinical samples, in vitro assays, and in vivo CLP models with genetic knockout
- Mechanistic mapping from post-translational modification (Ser886 dephosphorylation) to pathway activation and phenotype
Limitations
- Preclinical evidence without human interventional validation
- Potential off-target effects and safety concerns of Epothilone A not assessed in sepsis patients
Future Directions: Develop pharmacodynamic biomarkers for GEF-H1 activity, perform dose-finding and safety studies of GEF-H1 modulators, and validate Gzma/GEF-H1 pathway markers in human sepsis with barrier dysfunction.
BACKGROUND: Sepsis-induced intestinal injury is a severe complication associated with dysfunction affecting multiple organ systems and a significantly elevated risk of death. Intestinal barrier dysfunction plays a central role, but the underlying molecular pathways remain incompletely understood. The present study sought to explore how the Gzma/GEF-H1/RhoA signalling axis contributes to the disruption of the intestinal epithelial barrier in sepsis. METHODS: Transcriptomic data, clinical samples, and a murine caeca
2. Measuring signatures of host resistance, disease tolerance, and damage in human sepsis: a prospective cohort study.
In 444 prospectively enrolled ED sepsis patients, 16 plasma and urine biomarkers were organized into resistance, tolerance, and damage signatures. The damage signature independently associated with higher 90-day mortality, while tolerance trended protective and resistance was not significant; δ-type patients had higher damage and lower tolerance signatures than α-type.
Impact: Provides a mechanistically anchored biomarker framework that stratifies risk and aligns with recognized sepsis subtypes, advancing precision medicine efforts.
Clinical Implications: Damage-aligned biomarker signatures could inform early risk stratification and selection for organ-protective or immunomodulatory therapies, and guide subtype-specific trial design.
Key Findings
- Prospective enrollment of 444 Sepsis-3 patients within 6 hours of ED arrival with SENECA subtype assignment (α, β, γ, δ).
- A damage biomarker signature was associated with higher 90-day mortality (aOR 1.70, 95% CI 1.38–2.11; p<0.001).
- Resistance (aOR 0.83; p=0.4) and tolerance (aOR 0.83; p=0.06) signatures were not independently significant for mortality.
- Subtype differences: δ-type showed higher damage and lower tolerance; α-type showed lower damage and higher tolerance.
Methodological Strengths
- Prospective, early sampling within 6 hours and predefined subtype assignment (SENECA)
- Multimarker approach with expert-informed construct validity and PCA-based signatures with multivariable adjustment
Limitations
- Observational design limits causal inference and potential residual confounding
- External validation in independent cohorts is needed; clinical utility thresholds are not established
Future Directions: Externally validate signatures, define actionable thresholds, and test signature-guided therapeutic strategies in adaptive platform trials.
PURPOSE: To understand how protein biomarkers in blood and urine that are aligned with host resistance to infection, disease tolerance, and damage are associated with clinical outcomes and sepsis subtypes in community-onset sepsis. METHODS: Adults meeting Sepsis-3 criteria were prospectively enrolled within 6 h of emergency department arrival and assigned clinical subtypes (α, β, γ, δ), using the Sepsis ENdotyping in Emergency CAre (SENECA) approach. Using structured expert ranking with consensu
3. Performance of a Sepsis Prediction Model Across Different Sepsis Definitions.
In 198,494 encounters across 9 hospitals, a locally trained gradient-boosted model predicted sepsis every 15 minutes and was benchmarked against Sepsis-3, SEP-1, and ASE. Discrimination ranged from AUROC 0.85–0.94, precision was modest (AUPRC 0.11–0.24), and median lead time was 1.4–4.5 hours, highlighting definition-dependent performance and high false-positive rates.
Impact: Provides large-scale, multicenter evidence on the real-world performance and lead time of a deployed sepsis model across standard definitions, informing threshold selection and implementation.
Clinical Implications: Implementation should account for definition-dependent precision and alert burden; site-specific calibration, thresholds, and workflow integration are essential to mitigate false positives.
Key Findings
- Across 198,494 encounters, sepsis incidence varied by definition: 2.9% (Sepsis-3), 1.2% (SEP-1), and 2.0% (ASE).
- Model discrimination: AUROC 0.89 (Sepsis-3), 0.94 (SEP-1), 0.85 (ASE); precision (AUPRC) 0.24, 0.16, and 0.11, respectively.
- At the Sepsis-3 Youden top-left threshold, PPV was 11.4% with median lead time 3.4 hours; SEP-1 PPV 6.8 with 4.5-hour lead time; ASE PPV 5.9 with 1.4-hour lead time.
- High false-positive rates suggest careful thresholding and tailored implementation are required for clinical utility.
Methodological Strengths
- Large multicenter deployment with frequent (15-minute) predictions and evaluation against multiple computable sepsis definitions
- Comprehensive performance reporting including AUROC, AUPRC, PPV, and lead-time analyses
Limitations
- High false-positive rates may limit clinical utility without robust calibration and workflow integration
- Generalizability beyond the participating health system and external validation remain to be established
Future Directions: Prospective impact evaluations with clinician-in-the-loop, adaptive thresholding by care setting, and external validation across diverse EHRs and populations.
IMPORTANCE: Early detection of sepsis improves clinical outcomes, but the Early Detection of Sepsis Model, version 1 (Epic Systems Corp) has shown poor performance. Comparing sepsis models is complicated by varying outcome definitions and limited generalizability outside the development site. OBJECTIVE: To evaluate the Early Detection of Sepsis Model, version 2 using multiple standard sepsis definitions. DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study included all adult (aged ≥18 years) e